Patrick Loustau

Patrick Loustau serves as the President and Chief Executive Officer of Granite Bio since February 2025, following a notable tenure as Chief Business Officer at Amolyt Pharma until its acquisition by Alexion, AstraZeneca Rare Disease in July 2024. Previous experience includes Interim CEO at Zumbro Discovery, Inc., and President at Zafgen, Inc., where strategic leadership and development in biopharmaceuticals were key focuses. Loustau's extensive career also encompasses senior roles at Bristol-Myers Squibb and Novo Nordisk, emphasizing global commercialization, marketing, and organizational development in the healthcare sector. Educational credentials include advanced degrees from Harvard Business School, I.A.E. Bordeaux, and the University Paris-X, among others, specializing in general management, business, psychology, and physiology.